Why the study?
Do platelet-aggregation inhibitors prevent reinfarction and sudden death in patients with coronary heart disease?
Do platelet-aggregation inhibitors prevent reinfarction and sudden death in patients with coronary heart disease?
This review suggests a pragmatic approach to antithrombotic prophylaxis in coronary heart disease despite equivocal clinical trial results.
No takes yet. Share an insight, caveat, or question.
Supports pragmatic antithrombotic decisions in coronary disease despite uncertainty; leaves open the need for definitive trials.
William H. Frishman (1982) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: